Literature DB >> 7723210

Herpetic epithelial keratitis caused by acyclovir-resistant strain.

Y Mori1, Y Inoue, Y Shimomura.   

Abstract

Dendritic keratitis occurred during oral acyclovir (ACV) therapy in a 60-year-old man. Corneal stromal edema and iritis were found at his first visit. Herpetic keratouveitis was suspected, based on clinical findings and previous history. Treatment with steroid eyedrops and ACV ointment was initiated. However, ACV [corrected] ointment was changed to oral ACV, since conjunctival ulcer occurred as an adverse effect of the ointment. Subsequently, he received long-term oral ACV medication and steroid eyedrops for recurrent keratitis. The fifth recurrence was also treated with oral ACV and steroid eyedrops. At this time, although the stromal keratitis had improved, there was an outbreak of dendritic keratitis. The lesion healed spontaneously after only a reduction in the steroid. The 50% effective dose (ED)50 of the isolated virus to ACV was 4.4 +/- 0.15 micrograms/ml (mean +/- SD), a level considered ACV-resistant in vitro. The clinical course of this case emphasizes that it is important to consider the route and duration of ACV administration and the use of steroids in the treatment of stromal keratitis or keratouveitis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7723210

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  2 in total

1.  Clinical evaluation of carbocyclic oxetanocin G eyedrops in the treatment of herpes simplex corneal ulcers.

Authors:  H Shiota; K Nitta; T Naito; Y Mimura; T Maruyama
Journal:  Br J Ophthalmol       Date:  1996-05       Impact factor: 4.638

2.  Large Amounts of Reactivated Virus in Tears Precedes Recurrent Herpes Stromal Keratitis in Stressed Rabbits Latently Infected with Herpes Simplex Virus.

Authors:  Guey-Chuen Perng; Nelson Osorio; Xianzhi Jiang; Roger Geertsema; Chinhui Hsiang; Don Brown; Lbachir BenMohamed; Steven L Wechsler
Journal:  Curr Eye Res       Date:  2015-04-10       Impact factor: 2.424

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.